News
Client MNRs and Landing Pages
Since 2004, brands have counted on Cision’s MultiVu to create and distribute their important news and marketing content to the world.
Let's talkSearch our recent client collaborations below:
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 3, 2025International Paper (NYSE:IP; LSE: IPC) und DS Smith, zwei führende Hersteller von nachhaltigen Verpackungs-, Kartonage- und Zellstoffprodukten, haben am 31. Januar 2025We are stronger together. Learn more here. International Paper und DS Smith schließen sich zusammen, um den neuen Weltmarktführer für nachhaltige Verpackungslösungen zu schaffen French Spanish...
Jan 31, 2025SYMBRAVO represents a novel multi-mechanistic approach for the acute treatment of migraine that addresses the four key pathways underlying a migraine attackAxsome Therapeutics’ SYMBRAVO™ (meloxicam and rizatriptan) Approved by the U.S. Food and Drug Administration for the Acute Treatment of Migraine with or without Aura in Adults Lorem ipsum...
Jan 30, 2025Johnnie Walker continues its tradition with a limited edition Blue Label Lunar New Year bottle designed by James Jean, inviting whisky lovers to gift, savor and celebrate the Year of the SnakeJOHNNIE WALKER BLENDED SCOTCH WHISKY AND RONNY CHIENG CELEBRATE LUNAR NEW YEAR, HONORING TRADITIONS WHILE MAKING THEM YOUR OWN FOR A MEMORABLE CELEBRATION Johnnie Walker continues its tradition...
Jan 30, 2025Nurri Releases Vanilla Protein Milk Shake Just Four Months After Brand Debut, Meeting Growing DemandCostco’s Northwest region will be the first to get Nurri’s new Vanilla flavorLearn More Nurri Releases Vanilla Protein Milk Shake Just Four Months After Brand Debut, Meeting Growing Demand Costco’s Northwest region will be the first to get Nurri’s new Vanilla flavor...
Jan 28, 2025Ozempic® is now indicated to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney diseaseFDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease...
Connect with us: